Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 Aug 5;40(8):ivaf169.
doi: 10.1093/icvts/ivaf169.

Mid-Term Outcomes After Aortic Valve Replacement in Patients Under 70: A Comparative Study of INSPIRIS RESILIA Versus PERIMOUNT MAGNA EASE Bioprostheses

Gabriel Saiydoun  1   2 , Elie Nassar  3   4 , Saadé Saadé  5 , Chadi Aludaat  6 , Sylvain Rubin  3   4 , Ibrahim Alqdeimat  3 , Vito Giovanni Ruggieri  3   4
Affiliations
Comparative Study

Mid-Term Outcomes After Aortic Valve Replacement in Patients Under 70: A Comparative Study of INSPIRIS RESILIA Versus PERIMOUNT MAGNA EASE Bioprostheses

Gabriel Saiydoun et al. Interdiscip Cardiovasc Thorac Surg. .

Abstract

Objectives: INSPIRIS RESILIA, launched in 2017, is a bioprosthetic aortic valve developed to improve durability and facilitate future valve-in-valve procedures. Despite its advanced design, many surgeons continue to use the PERIMOUNT MAGNA EASE valve, which has long-standing clinical validation. This study aimed to compare mid-term clinical and echocardiographic outcomes in patients under 70 undergoing aortic valve replacement with either prosthesis.

Methods: We conducted a retrospective study of patients who underwent surgical aortic valve replacement between January 2018 and May 2023 at the University Hospital of Reims. The primary outcome was all-cause mortality at 1 year following surgical aortic valve replacement. Secondary outcomes included haemodynamic parameters, left ventricular ejection fraction, and major postoperative complications such as reintervention, stroke, pacemaker implantation, mediastinitis, transfusion, and new-onset atrial fibrillation.

Results: A total of 300 patients were included: 52 received the INSPIRIS RESILIA valve and 248 received the PERIMOUNT MAGNA EASE valve. After matching, 52 patients from each group were compared. All-cause mortality at 3 years was 0% in the INSPIRIS group and 1.9% in the PERIMOUNT group. Mean transvalvular gradients were similar at 1 year (11.3 vs 11.2 mmHg) and 3 years (12.9 mmHg for both). Two cases of endocarditis-related reoperation occurred in the INSPIRIS group. No structural valve degeneration requiring surgery was observed. Postoperative aortic regurgitation was trivial or absent. Transfusion rates were lower in the INSPIRIS group (46.1% vs 69.2%, P = .017).

Conclusions: INSPIRIS RESILIA and MAGNA EASE valves offer similar mid-term safety and performance in patients under 70 years of age.

Keywords: INSPIRIS RESILIA; PERIMOUNT MAGNA EASE; aortic stenosis; aortic valve replacement.

PubMed Disclaimer

Conflict of interest statement

C.A. reports receiving training and educational support from Edwards Lifesciences, Medtronic, and Abbott. There are no other potential conflicts of interest to declare.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
(A) Unadjusted survival probability estimate in the PERIMOUNT MAGNA EASE and the INSPIRIS RESILIA groups. (B) Propensity-matched survival probability estimates in the PERIMOUNT MAGNA EASE and the INSPIRIS RESILIA groups. Abbreviation: PSM, propensity score matching
Figure 2.
Figure 2.
Mean Gradients in the INSPIRIS RESILIA and PERIMOUNT MAGNA EASE Groups in Both the Unadjusted and Propensity-Matched Populations, According to Prosthesis Size. (A) Before hospital discharge; (B) at 1 year postoperatively; and (C) at 3 years postoperatively
See this image and copyright information in PMC

References

    1. Kostyunin AE, Yuzhalin AE, Rezvova MA, Ovcharenko EA, Glushkova TV, Kutikhin AG. Degeneration of bioprosthetic heart valves: update 2020. J Am Heart Assoc. 2020;9:e018506. - PMC - PubMed
    1. Bavaria JE, Mumtaz MA, Griffith B, et al. Five-year outcomes after bicuspid aortic valve replacement with a novel tissue bioprosthesis. Ann Thorac Surg. 2024;118:173-179. - PubMed
    1. Bavaria JE, Griffith B, Heimansohn DA, et al. ; COMMENCE Trial Investigators. Five-year outcomes of the COMMENCE trial investigating aortic valve replacement with RESILIA tissue. Ann Thorac Surg. 2023;115:1429-1436. - PubMed
    1. Bartus K, Litwinowicz R, Bilewska A, et al. Final 5-year outcomes following aortic valve replacement with a RESILIA tissue bioprosthesis. Eur J Cardiothorac Surg. 2021;59:434-441. - PMC - PubMed
    1. Sef D, Thet MS, Klokocovnik T, Luthra S. Early and mid-term outcomes after aortic valve replacement using a novel tissue bioprosthesis: a systematic review. Eur J Cardiothorac Surg. 2024;65:ezae045. - PubMed

Publication types

MeSH terms

LinkOut - more resources